Radiopharm Theranostics (ASX:RAD) Short-Term Debt: A$0.00 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Short-Term Debt?

Radiopharm Theranostics ASX:RAD Short-Term Debt is A$0.00 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Radiopharm Theranostics's Short-Term Debt for the quarter that ended in Jun. 2025 was A$0.00 Mil.

Radiopharm Theranostics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Radiopharm Theranostics Short-Term Debt Related Terms

Radiopharm Theranostics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Short-Term Debt Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Short-Term Debt
0.00 0.00 0.00 0.00

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Short-Term Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$0.00 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a Short-Term Debt of A$0.00 Mil as of Jun. 2025.
Is Radiopharm Theranostics' Short-Term Debt too high?
Radiopharm Theranostics' current Short-Term Debt is A$0.00 Mil.
How does Radiopharm Theranostics' Short-Term Debt compare to VRTX and REGN?
Radiopharm Theranostics' Short-Term Debt of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Radiopharm Theranostics's current Short-Term Debt is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Short-Term Debt of A$0.00 Mil. The current Short-Term Debt is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Short-Term Debt is A$0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.